logo-loader

Netscientific surges as peer-reviewed article confirms potential of PDS Biotech’s Versamune immunotherapy platform

Published: 15:50 16 May 2019 BST

cancer cell
The article was published online earlier this month and will be in next month’s print edition of Journal of Immunology

A peer-reviewed publication has given backing to a cancer immunotherapy platform developed by PDS Biotechnology Corporation (NASDAQ:PDSB) – one of Netscientific PLC’s (LON:NSCI) portfolio companies.

The article, published online earlier this month in the Journal of Immunology, describes how the Versamune platform recruits and activates T-cells.

READ: Netscientific soars as it sells stakes in Vortex and Wanda

T-cells are responsible for identifying and attacking cancer cells while at the same time making them more susceptible to T-cell attack.

A phase II study of PDS0101 – the lead drug from the Versamune platform – in combination with Merck’s Keytruda in head and neck cancer patients is due to kick off later this year.

Similar studies testing PDS0101 in advanced HPV-associated cancers and on its own in cervical dysplasia are also planned.

Shares in Netscientific, which owns 8.15% of PDS’s stock, rose 16.5% to 9.03p in late-afternoon trading on Thursday.

Wanda Health discusses its recent AI developments

Wanda Health Inc CEO Tom Smith visits the Proactive London studio to speak with Thomas Warner after the Remote Patient Monitoring (RPM) company announced the start of a new fundraise. Smith gives an overview of what Wanda intends to do with the proceeds, highlighting the company's sharp focus...

on 16/1/24